Articles related to HEART FAILURE (HF)
Peripartum cardiomyopathy presents a unique challenge in maternal health, with its late pregnancy symptoms often leading to delayed diagnosis. Understanding its hormonal and genetic underpinnings is vital for effective management.
Cardiology January 18th 2024
Label Mix-Up Prompts Recall of Heart Failure Medication
Marlex Pharmaceuticals has initiated a critical recall of specific lots of Digoxin Tablets due to a labeling error. Physicians are urged to exercise extreme caution and verify their inventory to prevent adverse patient outcomes.
Cardiology September 13th 2023
The Use of Technology to Improve Medication Adherence in Heart Failure Patients: A Systematic Review of Randomised Controlled Trials
Explore the potential of technology in enhancing medication adherence among heart failure patients and the need for more robust research in this area.
Cardiology June 30th 2023
Quadruple Therapy for Heart Failure Cost-effective Compared to Previous Standard of Care
Despite the demonstrated benefits of the recommended quadruple therapy for heart failure, its cost-effectiveness is highly sensitive to drug pricing, necessitating more thorough scrutiny and potential policy interventions to ensure equitable patient access.
Cardiology June 22nd 2023
Farxiga Approval Expands Use to More Patients With Heart Failure
Dive into how the FDA-approved Farxiga is changing the heart failure treatment landscape. Colleagues, let’s dive into a remarkable milestone. Farxiga, known as dapagliflozin, now has FDA approval. This is groundbreaking for heart failure treatment. It applies to all patients, regardless of their left ventricular ejection fraction (LVEF) status. The approval didn’t happen overnight. Let’s talk about the DELIVER trial, a vital part of the process. It involved over 6,000 patients, all over 40. Each had heart failure, LVEF above 40%, and may or may not have had type 2 diabetes. They took either dapagliflozin or a placebo daily, plus their usual therapy. The trial had a clear goal: time to the first composite event. This included CV death, heart failure hospitalization, or an urgent heart failure visit. The goal applied to everyone, including patients with LVEF less than 60%. Fast forward about 2.3 years, the results were significant. Dapagliflozin cut the composite outcome by 18% versus the placebo. Both worsening heart failure and CV death rates dropped in the dapagliflozin group. The best part? These findings were consistent, even in patients with lower LVEF or diabetes. Expanding the picture, let’s consider two trials together: DELIVER and DAPA-HF. Over 22 […]
Cardiology May 24th 2023